Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma

BACKGROUND: Lung squamous cell carcinoma (LUSC) remains a leading cause of cancer-related deaths with few therapeutic strategies. Immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy in patients with LUSC. However, ICIs could also lead to a unique spectrum of immune-related adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Minjiang, Ma, Pengfei, Zhang, Yongchang, Wang, Dong, Yu, Zhuang, Fu, Yujie, Zhao, Xiaojing, Wang, Mengzhao, Zhuang, Guanglei, Jing, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603341/
https://www.ncbi.nlm.nih.gov/pubmed/37857527
http://dx.doi.org/10.1136/jitc-2023-007305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603341/
https://www.ncbi.nlm.nih.gov/pubmed/37857527
http://dx.doi.org/10.1136/jitc-2023-007305

Ejemplares similares